6533b859fe1ef96bd12b78c9

RESEARCH PRODUCT

Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections

Ali A. RizviAles LinhartMichal VrablikEvangelos LiberopoulosRizzo Manfredi

subject

Dipeptidyl-Peptidase IV InhibitorsDiabetes Mellitus Type 2HumansHypoglycemic Agentsincretins diabetesPharmacology (medical)General MedicineIncretins10.1080/14740338.2022.2043848https://hdl.handle.net/10447/584546